Acelyrin Shares Are Trading Lower After the Company Announced Its Phase 2b/3 Study of Izokibep Did Not Meet Its Primary Endpoint, With Secondary Endpoints Also Failing to Achieve Statistical Significance.
Acelyrin Shares Are Trading Lower After the Company Announced Its Phase 2b/3 Study of Izokibep Did Not Meet Its Primary Endpoint, With Secondary Endpoints Also Failing to Achieve Statistical Significance.
艾希林股票下跌,因爲該公司宣佈其Izokibep的2b/3期研究未能達到主要終點,且次要終點也未能達到統計學意義。
Acelyrin Shares Are Trading Lower After the Company Announced Its Phase 2b/3 Study of Izokibep Did Not Meet Its Primary Endpoint, With Secondary Endpoints Also Failing to Achieve Statistical Significance.
艾希林股票下跌,因爲該公司宣佈其Izokibep的2b/3期研究未能達到主要終點,且次要終點也未能達到統計學意義。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。